Bogdan Cizmarevic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bogdan Cizmarevic has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andreja Zagorac
Laboratory of Medical Genetics, University Medical Centre Maribor, Maribor, Slovenia
2 shared publications - Boris Zagradišnik
Laboratory of Medical Genetics, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia
2 shared publications - Nadja Kokalj Vokač
Clinical Institute of Genetic Diagnostics, University Medical Centre Maribor, 2000 Maribor, Slovenia
2 shared publications - Bostjan Lanisnik
Department of Otolaryngology-Head and Neck Surgery, University Medical Center Maribor, Maribor, Slovenia.
1 shared publication Boštjan Lanišnik
University of Maribor, Faculty of Medicine; University Medical Centre, Department of Otorhinolaryngology, Cervical and Maxillofacial Surgery
1 shared publication- Boštjan Lanišnik
Department of Otorhinolaryngology, Head and Neck Surgery, Maribor University Medical Centre, 2000 Maribor, Slovenia
1 shared publication
Latest Publications
- Open Access
- 20 November 2021
- Published by University of Maribor in Acta Medico-Biotechnica
- Vol. 12 (1) , 31-39
Partial vs. superficial parotidectomy for surgical treatment of pleomorphic adenoma of the parotid gland
Purpose: Superficial parotidectomy is still the gold standard in surgical therapy for pleomorphic adenoma. Recently, less extensive procedures such as extracapsular dissection and before that partial parotidectomy were introduced. We analyzed the data of patients treated with either partial or superficial parotidectomy and compared recurrence rates and postoperative morbidity. Methods: WA retrospective analysis of all the patients with pleomorphic adenomas who were treated at the Department of Otolaryngology from 2002 to 2016 was performed. The patients’ data were analyzed for outcome measures: facial nerve deficit, margin status, Frey’s syndrome, tumor size, duration of surgery and tumor recurrence. Results: During this period, 186 patients with pleomorphic adenomas of the parotid gland underwent surgery, 177 of these for the first time. Nine patients were referred to us with recurrence from another institution. Among these 177 patients, 86 were treated by partial parotidectomy, 75 by superficial parotidectomy and 16 by total parotidectomy. Transient facial weakness and the duration of surgery differed significantly between the different types of operation. Frey’s syndrome and recurrence rate were not significantly different between the groups. Conclusions: Radical surgery could be achieved with limited removal of the parotid while the recurrence rate was the same between the groups.
- 20 November 2021
- Published by University of Maribor in Acta Medico-Biotechnica
- Vol. 12 (1) , 31-39
Open AccessPartial vs. superficial parotidectomy for surgical treatment of pleomorphic adenoma of the parotid gland
Purpose: Superficial parotidectomy is still the gold standard in surgical therapy for pleomorphic adenoma. Recently, less extensive procedures such as extracapsular dissection and before that partial parotidectomy were introduced. We analyzed the data of patients treated with either partial or superficial parotidectomy and compared recurrence rates and postoperative morbidity. Methods: WA retrospective analysis of all the patients with pleomorphic adenomas who were treated at the Department of Otolaryngology from 2002 to 2016 was performed. The patients’ data were analyzed for outcome measures: facial nerve deficit, margin status, Frey’s syndrome, tumor size, duration of surgery and tumor recurrence. Results: During this period, 186 patients with pleomorphic adenomas of the parotid gland underwent surgery, 177 of these for the first time. Nine patients were referred to us with recurrence from another institution. Among these 177 patients, 86 were treated by partial parotidectomy, 75 by superficial parotidectomy and 16 by total parotidectomy. Transient facial weakness and the duration of surgery differed significantly between the different types of operation. Frey’s syndrome and recurrence rate were not significantly different between the groups. Conclusions: Radical surgery could be achieved with limited removal of the parotid while the recurrence rate was the same between the groups.
- Open Access
- 15 January 2018
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 11 (1) , 1-9
Identification of genomic copy number variations associated with specific clinical features of head and neck cancer
Copy number variations (CNSs) of large genomic regions are an important mechanism implicated in the development of head and neck cancer, however, for most changes their exact role is not well understood. The aim of this study was to find possible associations between gains/losses of genomic regions and clinically distinct subgroups of head and neck cancer patients. Array comparative genomic hybridization (aCGH) analysis was performed on DNA samples in 64 patients with cancer in oral cavity, oropharynx or hypopharynx. Overlapping genomic regions created from gains and losses were used for statistical analysis. Following regions were overrepresented: in tumors with stage I or II a gain of 2.98 Mb on 6p21.2-p11 and a gain of 7.4 Mb on 8q11.1-q11.23; in tumors with grade I histology a gain of 1.1 Mb on 8q24.13, a loss of a large part of p arm of chromosome 3, a loss of a 1.24 Mb on 6q14.3, and a loss of terminal 32 Mb region of 8p23.3; in cases with affected lymph nodes a gain of 0.75 Mb on 3q24, and a gain of 0.9 Mb on 3q26.32-q26.33; in cases with unaffected lymph nodes a gain of 1.1 Mb on 8q23.3, in patients not treated with surgery a gain of 12.2 Mb on 7q21.3-q22.3 and a gain of 0.33 Mb on 20q11.22. Our study identified several genomic regions of interest which appear to be associated with various clinically distinct subgroups of head and neck cancer. They represent a potentially important source of biomarkers useful for the clinical management of head and neck cancer. In particular, the PIK3CA and AGTR1 genes could be singled out to predict the lymph node involvement.
- 15 January 2018
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 11 (1) , 1-9
Open AccessIdentification of genomic copy number variations associated with specific clinical features of head and neck cancer
Copy number variations (CNSs) of large genomic regions are an important mechanism implicated in the development of head and neck cancer, however, for most changes their exact role is not well understood. The aim of this study was to find possible associations between gains/losses of genomic regions and clinically distinct subgroups of head and neck cancer patients. Array comparative genomic hybridization (aCGH) analysis was performed on DNA samples in 64 patients with cancer in oral cavity, oropharynx or hypopharynx. Overlapping genomic regions created from gains and losses were used for statistical analysis. Following regions were overrepresented: in tumors with stage I or II a gain of 2.98 Mb on 6p21.2-p11 and a gain of 7.4 Mb on 8q11.1-q11.23; in tumors with grade I histology a gain of 1.1 Mb on 8q24.13, a loss of a large part of p arm of chromosome 3, a loss of a 1.24 Mb on 6q14.3, and a loss of terminal 32 Mb region of 8p23.3; in cases with affected lymph nodes a gain of 0.75 Mb on 3q24, and a gain of 0.9 Mb on 3q26.32-q26.33; in cases with unaffected lymph nodes a gain of 1.1 Mb on 8q23.3, in patients not treated with surgery a gain of 12.2 Mb on 7q21.3-q22.3 and a gain of 0.33 Mb on 20q11.22. Our study identified several genomic regions of interest which appear to be associated with various clinically distinct subgroups of head and neck cancer. They represent a potentially important source of biomarkers useful for the clinical management of head and neck cancer. In particular, the PIK3CA and AGTR1 genes could be singled out to predict the lymph node involvement.
- Open Access
- 1 January 2014
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 7 (1) , 5
An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas
Oral and oropharyngeal squamous cell carcinomas (OSCC) are among the most common cancers. The poor survival rate among oral cancer patients can be attributed to several factors, one of them being lack of early detection. A key approach to this problem would be to detect potentially malignant lesion at their early stage. Using the FISH technique, oral brush cytology slides can be an easy and rapid screening approach for malignant cell detection. The present study was designed to detect hTERC and SOX2 amplifications in OSSC exfoliative tumor cells and evaluate whether those two gene amplifications might serve as a supportive biomarker in early detection and diagnosis of oral and oropharyngeal SCC.
- 1 January 2014
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 7 (1) , 5
Open AccessAn evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas
Oral and oropharyngeal squamous cell carcinomas (OSCC) are among the most common cancers. The poor survival rate among oral cancer patients can be attributed to several factors, one of them being lack of early detection. A key approach to this problem would be to detect potentially malignant lesion at their early stage. Using the FISH technique, oral brush cytology slides can be an easy and rapid screening approach for malignant cell detection. The present study was designed to detect hTERC and SOX2 amplifications in OSSC exfoliative tumor cells and evaluate whether those two gene amplifications might serve as a supportive biomarker in early detection and diagnosis of oral and oropharyngeal SCC.
- 1 November 2012
- p. 27-32
Cervical lymph node metastasis of squamous cell carcinoma from unknown primary tumor.
The first aim of the study was to determine the survival rate of the patients with Carcinoma of the Unknown Primary (CUP) in relation to lymph node status and eventual later identification of the primary tumor. To second one was to investigate the impact of PET-CT on identification of the primary tumor. We studied 97 patients sent to our University Medical Center with diagnosis of metastasis of unknown primary tumor between 1.1.1997 and 1.9.2009. All patients had panendoscopy and some had PET-CT at later period. All susceptible patients had a surgery and postoperative radiation therapy. After the completed their treatment they were followed up at ENT department. With preoperative examinations we discovered 48 primary tumors. Only in one case of 13 the PET-CT detected the primary tumor not confirmed with other examination methods. After the treatment we found primary tumors in 10 patients. In 39 patients we didn't discover any primary tumor. The 2-year overall survival for 10 patients with found tumor was 80.0%, the 2-year overall survival for the 39 patients without discovered tumor was 73.8%. The 2-year disease-specific survival for 10 patients with found tumor was 90.0%, the 2-year disease-specific survival for 39 patients without discovered tumor was 81.6%. The 2-year overall survival for high neck level lymph node metastasis group (N = 36) was 80.1%, the 2-year overall survival for low neck level lymph node group (N = 13) was 61.5%. PET-CT method was not particularly useful in detecting primary tumors in patients with metastasis with unknown primary. Patients with high neck level lymph node metastasis had statistically significant better survival.
- 1 November 2012
- p. 27-32
Cervical lymph node metastasis of squamous cell carcinoma from unknown primary tumor.
The first aim of the study was to determine the survival rate of the patients with Carcinoma of the Unknown Primary (CUP) in relation to lymph node status and eventual later identification of the primary tumor. To second one was to investigate the impact of PET-CT on identification of the primary tumor. We studied 97 patients sent to our University Medical Center with diagnosis of metastasis of unknown primary tumor between 1.1.1997 and 1.9.2009. All patients had panendoscopy and some had PET-CT at later period. All susceptible patients had a surgery and postoperative radiation therapy. After the completed their treatment they were followed up at ENT department. With preoperative examinations we discovered 48 primary tumors. Only in one case of 13 the PET-CT detected the primary tumor not confirmed with other examination methods. After the treatment we found primary tumors in 10 patients. In 39 patients we didn't discover any primary tumor. The 2-year overall survival for 10 patients with found tumor was 80.0%, the 2-year overall survival for the 39 patients without discovered tumor was 73.8%. The 2-year disease-specific survival for 10 patients with found tumor was 90.0%, the 2-year disease-specific survival for 39 patients without discovered tumor was 81.6%. The 2-year overall survival for high neck level lymph node metastasis group (N = 36) was 80.1%, the 2-year overall survival for low neck level lymph node group (N = 13) was 61.5%. PET-CT method was not particularly useful in detecting primary tumors in patients with metastasis with unknown primary. Patients with high neck level lymph node metastasis had statistically significant better survival.